Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Andrea Visentin, Lydia Scarfò, Thomas Chatzikonstantinou, Anargyros Kapetanakis, Christos Demosthenous, Georgios Karakatsoulis, Martin Andres, Darko Antic, David Allsup, Mónica Baile, Dominique Bron, Antonella Capasso, Mark Catherwood, Rosa Collado, Raul Cordoba, Carolina Cuéllar-García, Julio Delgado, Maria Dimou, Michael Doubek, Lorenzo De Paoli, Maria Rosaria De Paolis, Giovanni Del Poeta, Maria Efstathopoulou, El-Ashwah Shimaa, Alicia Enrico, Lucia Farina, Angela Ferrari, Myriam Foglietta, Moritz Furstenau, Jose A. Garcia-Marco, Massimo Gentile, Eva Gimeno, Gomes da Silva Maria, Odit Gutwein, Yervand Hakobyan, Yair Herishanu, jose Angel Hernandez, Tobias Herold, Sunil Iyengar, Gilad Itchaki, Ozren Jaksic, Ann Janssens, Olga Kalashnikova, Elzbieta Kalicinska, Arnon P. Kater, Sabina Kersting, Jorge Labrador, Deepesh Lad, Luca Laurenti, Mark-David Levin, Enrico Lista, Lara Malerba, Roberto Marasca, Monia Marchetti, Juan Marquet Palomanes, Mattias Mattsson, Francesca Romana Mauro, Carlota Mayor-Bastida, Marta Morawska, Marina Motta, Talha Munir, Roberta Murru, Ivana Milosevic, Fatima Miras Calvo, Carsten Utoft Niemann, Jacopo Olivieri, Lorella Orsucci, Maria Papaioannou, Miguel Arturo Pavlovsky, Inga S. Piskunova, Barbara Pocali, Viola Maria Popov, Francesca Maria Quaglia, Giulia Quaresmini, Doreen te Raa, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Amit Shrestha, Martin Šimkovič, Martin Špaček, Paolo Sportoletti, Oana Stanca Ciocan, Tamar Tadmor, Elisabeth Vandenberghe, Marzia Varettoni, Candida Vitale, Ellen Van Der Spek, Michel Van Gelder, Ewa Wasik-Szczepanek, Lucrecia Yáñez, Mohamed A Yassin, Marta Coscia, Barbara Eichhorst, Alessandro Rambaldi, Niki Stavroyianni, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2022) 140 (Supplement 1): 2333–2337.

https://doi.org/10.1182/blood-2022-163259

Published: 2022

Journal Articles

Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD - Primary Analysis from the Randomized Phase II Vision HO141 Trial

Blood (2021) 138 (Supplement 1): 69.

https://doi.org/10.1182/blood-2021-148630

Published: 2021

Journal Articles

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, Manja Meggendorfer, Ferran Nadeu, Christian Brieghel, Helen Parker, Stamatia Laidou, Riccardo Moia, Davide Rossi, Mark Catherwood, Jana Kotaskova, Julio Delgado, Ana E Rodríguez-Vicente, Rocio Benito, Gian Matteo Rigolin, Silvia Bonfiglio, Lydia Scarfo, Mattias Mattsson, Zadie Davis, Ajay Gogia, Lata Rani, Panagiotis Baliakas, Cecilia Jylhä, Aron Skaftason, Inmaculada Rapado, Fatima Miras, Joaquin Martinez-Lopez, Javier de la Serna, Jesús M Hernández Rivas, Patrick Thornton, Maria Jose Larrayoz, María José Calasanz, Zoltán Mátrai, Csaba Bodor, Karin E. Smedby, Blanca Espinet, Anna Puiggros, Ritu Gupta, Lars Bullinger, Francesc Bosch, Bárbara Tazón, Fanny Baran-Marszak, David Oscier, Florence Nguyen-Khac, Thorsten Zenz, María José Terol, Antonio Cuneo, María Hernández-Sánchez, Sarka Pospisilova, Ken I Mills, Gianluca Gaidano, Carsten Utoft Niemann, Elías Campo, Jonathan C Strefford, Paolo Ghia, Kostas Stamatopoulos, Richard Rosenquist

Blood (2021) 138 (Supplement 1): 2617.

https://doi.org/10.1182/blood-2021-150648

Published: 2021

Journal Articles

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

Blood (2021) 137 (8): 1117–1120.

https://doi.org/10.1182/blood.2020008608

Published: 2021

Includes: Supplemental data

Journal Articles

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

Blood (2020) 135 (21): 1859–1869.

https://doi.org/10.1182/blood.2019003453

Published: 2020

Includes: Supplemental data

Journal Articles

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

Caspar Da Cunha-Bang, MD PhD, Rudy Agius, Arnon P. Kater, Mark-David Levin, MD PhD, Anders Österborg, MD PhD, Mattias Mattsson, MD, Carsten Utoft Niemann, MD PhD

Blood (2019) 134 (Supplement_1): 4304.

https://doi.org/10.1182/blood-2019-121907

Published: 2019

Journal Articles

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Blood (2019) 134 (Supplement_1): 4292.

https://doi.org/10.1182/blood-2019-124377

Published: 2019

Journal Articles

Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Rise—a Nationwide Population-Based Study from Sweden

Mattias Mattsson, MD, Fredrik Sandin, Eva Kimby, MD PhD, Martin Höglund, MD PhD, Ingrid Glimelius, MD PhD

Blood (2018) 132 (Supplement 1): 3120.

https://doi.org/10.1182/blood-2018-99-114058

Published: 2018

Journal Articles

A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression

Blood (2018) 132 (Supplement 1): 1834.

https://doi.org/10.1182/blood-2018-99-116325

Published: 2018

Journal Articles

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

Maria Winqvist, MSc, MD, Per-Ola Andersson, MD PhD, Anna Asklid, MD, Karin Karlsson, MD, Claes Karlsson, MD PhD, Birgitta Lauri, MD, Jeanette Lundin, MD PhD Assoc Prof, Mattias Mattsson, MD, Stefan Norin, MD PhD, Anna Bergendahl Sandstedt, MD, Lotta Hansson, Anders Österborg, MD PhD Prof.

Blood (2017) 130 (Supplement 1): 5353.

https://doi.org/10.1182/blood.V130.Suppl_1.5353.5353

Published: 2017

Journal Articles

Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Sandra Eketorp Sylvan, MD PhD, Anna Asklid, MD, Hemming Johansson, Jenny Klintman, MD PhD, Jenny Bjellvi, MD, Staffan Tolvgård, MD, Eva Kimby, Stefan Norin, MD PhD, P-O Andersson, MD PhD Prof., Claes Karlsson, MD PhD, Karin Karlsson, MD, Birgitta Lauri, MD, Mattias Mattsson, MD, Anna Bergendahl Sandstedt, MD, Maria Strandberg, MD, Anders Österborg, MD PhD Prof., Lotta Hansson

Blood (2017) 130 (Supplement 1): 1744.

https://doi.org/10.1182/blood.V130.Suppl_1.1744.1744

Published: 2017

Journal Articles

Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites

Andreas Agathangelidis, Anastasia Hadzidimitriou, Eva Minga, Lesley-Ann Sutton, Eleftheria Polychronidou, Tait D. Shanafelt, MD, Zadie Davis, Xiao-Jie Yan, MD PhD, Karla Plevova, Myriam Boudjoghra, Alba Navarro, Davide Rossi, Lone Bredo Pedersen, Vasilis Bikos, Panagiotis Baliakas, Lydia Scarfò, MD, Mattias Mattsson, Aliki Xochelli, MD PhD, Paola Francia di Celle, Krzysztof Giannopoulos, Katrina Vanura, Ludo Evers, Silvio Veronese, Monica Facco, Panagiotis Moschonas, Vojtech Bystry, Teodora Karan-Djurasevic, Maria Roumelioti, Sonja Pavlovic, Larry Mansouri, Charles Chu, Evangelia Stalika, Veronique Giudicelli, Panagiotis Panagiotidis, Andrey Sudarikov, Achilles Anagnostopoulos, Livio Trentin, MD, Mark Catherwood, Marco Montillo, MD, Niki Stavroyianni, MD, Gianluca Gaidano, Elias Campo, Carsten Utoft Niemann, Anton W. Langerak, Sarka Pospisilova, Marie-Paule Lefranc, Ulrich Jaeger, Arnon Kater, MD PhD, Christiane Pott, Nicholas Chiorazzi, MD, David Oscier, Diane F. Jelinek, Stephan Stilgenbauer, Michael Hallek, Dimitrios Tzovaras, Nikos Darzentas, Chrysoula Belessi, Frederic Davi, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos, MD PhD

Blood (2016) 128 (22): 4376.

https://doi.org/10.1182/blood.V128.22.4376.4376

Published: 2016

Journal Articles

Tailored Approaches for Refined Prognostication in Chronic Lymphocytic Leukemia Patients with Mutated Versus Unmutated Immunoglobulin Receptors

Blood (2016) 128 (22): 3199.

https://doi.org/10.1182/blood.V128.22.3199.3199

Published: 2016

Journal Articles

An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL

Joan Ballesteros, Lydia Scarfo, Mattias Mattsson, Aliki Xochelli, Pamela Ranghetti, Daniel Primo, Alicia Robles, Julian Gorrochategui, Joaquin Martinez-Lopez, Javier De la Serna, Marcos González, MD PhD, Veerendra Munugalavadla, Richard Rosenquist, Kostas Stamatopoulos, Christophe Quéva, PhD, Paolo Ghia, MD PhD

Blood (2015) 126 (23): 2485.

https://doi.org/10.1182/blood.V126.23.2485.2485

Published: 2015

Journal Articles

Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?

Blood (2015) 126 (23): 2921.

https://doi.org/10.1182/blood.V126.23.2921.2921

Published: 2015

Journal Articles

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

Lotta Hansson, MD PhD, Maria Winqvist, MD, Anna Asklid, MD, P-O Andersson, MDPhD, Karin Karlsson, MD, Claes Karlsson, MDPhD, Birgitta Lauri, MD, Jeanette Lundin, MD PhD, Mattias Mattsson, MD, Stefan Norin, MDPhD, Anna Sandstedt, MD, Anders Österborg, MDPhD

Blood (2015) 126 (23): 1745.

https://doi.org/10.1182/blood.V126.23.1745.1745

Published: 2015

NARROW

Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD - Primary Analysis from the Randomized Phase II Vision HO141 Trial

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia

PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) - 15-Month Safety, Response and MRD Evaluation: Third Interim Analysis from the Phase II Vision HO141 Trial

Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Rise—a Nationwide Population-Based Study from Sweden

A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites

Tailored Approaches for Refined Prognostication in Chronic Lymphocytic Leukemia Patients with Mutated Versus Unmutated Immunoglobulin Receptors

An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL

Personalized Modeling of Disease Evolution in CLL: Does Statistical Significance Translate into Predictive Accuracy?

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only